Furthermore, the growth of renal cell carcinoma (Gemmill et al, 2005), glioblastoma multiforme (Goudar et al, 2005), as well as non-small-cell lung cancer, pancreatic, colon, and breast (Buck et al, 2006) cancers were synergistically reduced when EGFR inhibitors were combined with the mTOR inhibitor rapamycin. The gene discussed is EGFR; the disease is cancer.